A Massachusetts Man Says Ozempic Blinded Him. Now the FDA Requires a NAION Warning on Every GLP-1.

A Massachusetts Man Says Ozempic Blinded Him. Now the FDA Requires a NAION Warning on Every GLP-1.

A Massachusetts Man Says Ozempic Blinded Him. Now the FDA Requires a NAION Warning on Every GLP-1.Dr. Kate Dee
Published on: 08/11/2026

The FDA now requires a NAION vision-loss warning on every GLP-1, including Ozempic, Wegovy and Zepbound. What the data shows and what prescribers should do.

NAIONFDA GLP-1 warningOzempic blindness lawsuitsemaglutide NAIONtirzepatide NAIONGLP-1 vision lossWegovy side effectsZepbound side effectscompounded semaglutidecompounded tirzepatideMDL 3163optic nerve strokeGLP-1 informed consentGLP-1 label changepeptide safety
Peptides Are Not Being Approved. They May Be Allowed. That Is Not the Same Thing.

Peptides Are Not Being Approved. They May Be Allowed. That Is Not the Same Thing.

Peptides Are Not Being Approved. They May Be Allowed. That Is Not the Same Thing.Dr. Kate Dee
Published on: 21/10/2026

An FDA peptide compounding policy is under review. It is not approval. What medspas need to know about BPC-157, enforcement discretion, and prescriber risk.

FDA peptidespeptide interim access policycompounded peptidesBPC-157BPC-157 legalpeptide therapy medspaenforcement discretion503A bulks listTB-500research use only peptidespeptide safetycompounding pharmacymedspa complianceunapproved drugsMedSpa Board